Skip to main content
DIRUI INDUSTRIAL CO.,LTD. logo

DIRUI INDUSTRIAL CO.,LTD. — Investor Relations & Filings

Ticker · 300396 ISIN · CNE100001XS7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,689 across all filing types
Latest filing 2021-08-23 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300396

About DIRUI INDUSTRIAL CO.,LTD.

https://www.dirui.com.cn

DIRUI INDUSTRIAL CO.,LTD. specializes in the research, development, manufacturing, and distribution of medical laboratory instruments and diagnostic reagents. The company provides comprehensive solutions for in-vitro diagnostics (IVD), focusing on several key clinical areas including urinalysis, biochemistry, hematology, and chemiluminescence immunoassay. Its product portfolio features high-throughput automated analyzers and integrated laboratory systems designed to enhance diagnostic efficiency and accuracy. DIRUI serves a global market, providing medical institutions and laboratories with a wide range of diagnostic tools, from urine sediment analysis to vaginal secretion testing. The company emphasizes technological innovation and quality control to support clinical decision-making and patient care through reliable laboratory automation and standardized testing protocols.

Recent filings

Filing Released Lang Actions
2021年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "迪瑞医疗科技股份有限公司 2021 年半年度报告全文" which translates to "Dirui Medical Technology Co., Ltd. 2021 Semi-Annual Report Full Text." It explicitly states it is a half-year report covering the period from January 1, 2021 to June 30, 2021. The content includes detailed financial data, management discussion and analysis, company overview, business segments, and regulatory compliance information. The length is substantial (15,000 characters), and it contains actual financial statements and substantive analysis, not just an announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-23 Chinese
关于公司申报医疗器械注册获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acceptance of medical device registration applications by a regulatory authority (Jilin Province Drug Administration). It details the products involved and the current status of the registration process. There is no financial data, no mention of financial results, no management discussion, no voting results, no executive changes, no legal proceedings, and no report publication. The document is a regulatory announcement about product registration acceptance, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2021-08-23 Chinese
监事会决议公告
Report Publication Announcement Classification · 95% confidence The document is a formal announcement of the supervisory board meeting resolution regarding the company's 2021 semi-annual report. It states that the supervisory board has reviewed and approved the 2021 half-year report and its summary, confirming compliance with legal and regulatory requirements. The document does not contain the actual financial statements or detailed report content but refers readers to the full report available on an external website. The document length is short (707 characters), and it serves as an announcement of the report's approval rather than the report itself. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) rather than an Interim/Quarterly Report (IR).
2021-08-23 Chinese
关于2021年半年度报告披露的提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (278 characters) indicating that the company's 2021 half-year (semi-annual) report has been published and is available on the designated disclosure website. It does not contain the actual report or financial data but serves as a notice to investors to review the report elsewhere. According to the 'MENU VS MEAL' rule, such a brief notice about report availability is classified as a Report Publication Announcement (RPA).
2021-08-23 Chinese
迪瑞医疗：关于第五届董事会第三次会议相关事项的独立董事意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion related to the company's fifth board meeting held on August 23, 2021. It discusses specific matters such as related party fund occupation and external guarantees, referencing compliance with stock exchange listing rules and company articles. The document is short (621 characters) and focuses on board/management related disclosures rather than financial results or audit findings. It is not a full annual report, audit report, or earnings release. It is not a voting result or proxy solicitation. The content aligns with announcements about board or management information, specifically independent directors' opinions on board meeting matters. Therefore, the document fits best under Board/Management Information (MANG).
2021-08-23 Chinese
2021年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2021 半年度报告摘要' which translates to '2021 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period, including revenue, net profit, earnings per share, and other financial indicators. It also discusses business operations, market conditions, and strategic initiatives during the reporting period. The presence of comprehensive financial figures and business analysis indicates this is a substantive interim financial report rather than a brief announcement or summary. The document length is 4677 characters, which is sufficient for a detailed interim report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-23 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.